Christine BrennanPartner at MRL Ventures Fund
Christine has over 15 years in the life-science industry including business development, corporate strategy and venture investing. She is currently Partner at MRL Ventures Fund (MRLV). She was previously on the board of Altimmune (NASDAQ:ALT) and an observer on the boards on a number of companies including ROX Medical, Innocrin Pharmaceuticals, Quartet Medicine and Viamet Pharmaceuticals. She is currently responsible for MRLV’s investments in Entrada Therapeutics, Alector (NASDAQ:ALEC) and Translate Bio (NASDAQ:TBIO).
Prior to MRLV, she was Principal at the Novartis Venture Fund from 2013-2017 and Chief Business Officer at Vitae Pharmaceuticals from 2010-2013. She also held positions in business development and marketing at small biopharmaceutical and large pharmaceutical companies. Christine received her Ph.D. in neuroscience from Dartmouth Medical School and did post-doctoral research in developmental neurobiology at the National Institutes of Health.